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In Vitro Complement Activation by Intercellular Antibodies 
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By in vitro complement immunofluorescence, 6 sera 
from pemphigus with intercellular antibodies were 
tested for their capability to fix Clq, C4, C3, and proper-
din. All 6 serum samples yielded positive reaction for C3 
staining. Three serum samples gave positive staining for 
Clq, 5 serum samples for C4, and 3 serum samples for 
properdin, respectively. Substitution of C2 deficient se-
rum as a complement source inhibited C3 and properdin 
staining but not positive Clq and C4 staining. These 
results are best explained by the concept that comple-
ment activation in vitro by intercellular antibodies oc-
curs via the classical pathway followed by assembly of 
the C3 amplification mechanism. 
Although the deposition of complement components in the 
intercellular (IC) areas of the lesional skin of the pemphigus 
patients is frequently seen [1,2], circulating IC antibodies were 
thought not to flx complement by complement immunofluores-
cence (CIF) for a long time [3]. However, in our previous studies 
[4,5], we have shown complement fIxing (CF) IC antibodies in 
some sera of untreated pemphigus patients, and several inves-
tigations have shown many evidences that complement system 
should play an important role in pemphigus acantholysis [6-
9]. In the present study, we investigated further the complement 
activating pathway of CF IC antibodies in vitro. 
MATERIALS AND METHODS 
Serum 
Sera were obtained from 6 untreated patients with various forms of 
pemphigus who were diagnosed clinically, histologically and irnmuno-
pathologically, and were stored at -20°C. They were inactivated at 
56°C for 30 min at the time of the experiment. Sera from one each case 
of bullous pemphigoid and mixed connective tissue disease (MCTD) 
were used as controls in CIF. 
Source of Complement 
The fresh normal human serum (NHS) used as a source of comple-
ment in CIF was obtained from a normal volunteer and stored at -70°C 
until use and was diluted 1:5 in phosphate buffered saline (PBS) with 
MgH and Ca++. Heat inactivated NHS and C2 deficient human serum 
[10] (a gift from Dr. S. R. Pinnell, Duke University Medical Center, . 
U.S.A.) was used as control in CIF. 
Immunofluorescence and Antisera 
Indirect immunofluorescence (IlF) and ClF for Clq, C4, C3 and 
properdin were performed by the standard procedure as described 
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Abbreviations: 
CIF: complement immunofluorescence ' 
CF: complement fixing 
IC: in tercellular 
IIF: indu·ect immunofluorescence 
MCTD: mixed connective tissue disease 
NHS: normal human serum 
PBS: phosphate buffered saline 
elsewhere [11,12). For the staining, commercially available conj ugates 
for human IgG, Clq, C4, C3, and rabbit IgG were used, and rabbit 
antiproperdin antiserum was kindly supplied by the Coul'tesy of Dr. F. 
Kaneko (Hokkaido University School of Medicine, Japan). The anti-
body titer and the final dilution of the conjugates were as follows; for 
human IgG, 1:10 (Dakopatts Co" Denmark, y-chain specific, Lot 089A 
DAKO antibody titer 200), for Clq, 1:10 (Behring Institute, W. Ger: 
many, Lot 1289D5H, specific antibody content 2.0 mg/ m\), for C4, 1:10 
(Behring Institute, W. Germany, Lot 129208A, specific antibody content 
2.5 mg/ml), for C3, 1:10 (Dakopatts Co., Denmark, Lot 124 , DAKO 
antibody titer 100) and for rabbit IgG, 1:16 (Dakopatts Co., Denmark 
heavy and light chain specific, Lot 037) , The procedure of the prepa: 
ration and the specificity test of the antiproperdin antiserum wa 
described elsewhere [13], and it was used at 1:10 dilution. For the 
blocking test, unlabeled antisera were purchased from Behring Insti-
tute, W. Germany; for C1q (Lot 128905H, antibody titer 3.0 mg/ ml) , for 
C4 (Lot 129208A, antibody titer 1.0 mg/m!) and C3 (Lot 5104B, anti-
body t iter l.3 mg/ ml) , and were used at 1:2.5 dilu tion . The stained 
specimens were examined with a Tiyoda fluorescence microscope 
equipped with Osram HBO 200 mercury vapor lamp and dal·k field 
condenser. 
RESULTS 
As shown in Table I, IC antibodies were demonstrated in all 
6 cases in titers ranging from 1:40 to 1:160 as observed by IIF. 
Positive C1q fixation was revealed by CIF at 1:5 serum dilution 
in 3 cases, C4 in 5 cases (Fig 1), C3 in all 6 cases and properdin 
in 3 cases (Fig 2) , The titer of positive C1q, C4, C3 and properdin 
in selected 2 cases was 1:5 for C1q, 1:20 for C4, 1:40 and 1:10 for 
C3 and 1:20 and 1:5 for properdin, respectively. By the control 
sera of bullous pemphigoid and MCTD, positive C1q, C4, C3 
and properdin staining were observed at the basement m em-
brane zone and the nucleus of epidermal cells, respect ively. 
Control tests for CIF were performed as shown in Table II and 
standard control tests confu·med the specificity of CIF. In 
addition, blocking tests for FITC labeled anti-C1q, C4 and C3 
antisera disclosed the specificity of each labeled antiserum for 
complement components. When C2 deficient human serum was 
substituted for NHS as a complement source, complete inhibi-
tion of both C3 and properdin staining was apparent, while Clq 
and C4 staining was not diminished at all. 
DISCUSSION 
Using direct immunofluorescence and modified IIF, comple-
ment components of both classical (Clq and C4) and alternative 
(Factor B and properdin) pathways have been demonstrated in 
the IC areas of the pemphigus lesional skin in addition to IgG 
[1,2]. Moreover, in the case of bullous pemphigoid, Jordon et al 
[12,14] have shown that circulating basement membrane zone 
antibodies fix Clq, C4, and properdin in addition to C3 in vitro_ 
Using C2 deficient serum substituted for NHS as complem ent 
source, the positive C3 and properdin staining was not shown. 
Therefore, they concluded that the complement activation by 
circulating pemphigoid antibodies occurs via the classical path-
way followed by assembly of the C3 amplification m echanism 
[14]. 
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Our previous studies demonstrated that some IC antibodies 
fix C3 using CIF [4,5]. In the present study, we demonstrated 
further that CF IC antibodies fix C1q, C4, and properdin in 
addition to C3. These findings would explain the frequent 
occurrence of C1q, C4, C3 and properdin deposition in pemphi-
gus lesional skin [1,2]. The positive Clq and C4 fixation con-
firms more strongly that the complement activation by the Ie 
antibodies occurs via the classical pathway following immune 
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TABLE I. Detection of the complement activating pathway for the circu.lating intercellular antibodies in pemphigus 
lI F Complement im munofluorescence 
No. Case Diagnosis 
IgG Clq C4 C3 Properdin 
1 TN Pem." vulgaris 40 5 20 40 20 
2 IK Pem. vu lgaris 80 +" 20 + 
3 MM Pem. vu lgaris 160 20 
4 KK P em. erythematosus 80 5 20 10 5 
5 YK P em. foliaceus 80 + 20 
6 NO Pem. e ry thematosus 160 + + 40 
Total 6/ 6 3/6 5/ 6 6/6 3/ 6 
" Pem: Pemphigus. 
b + : Tested at titer 1:5. 
C _ : Negative at titer 1:5. 
FIG L Positive binding of C4 to the IC areas of the epidermis (CIF, 
reduced from X 400). 
FIG 2. P ositive binding of properdin to t he IC areas of the huma n 
epidermis (CIF, reduced from X 200). 
TABLE II. Control tests for comple;nent imI/l.T1I l1no(lu.orescellce 
Sample 
Saline No C/' 
Complement 
treaiment. 
Saline C at 37°C 
NHS (1:5) C at 37°C 
Pemphigus serum 
1:5 No C 
1:5 C at 37°C 
1:5 C at 27°C 
1:5 Heat inactivated C at 37°C 
1:5 C at 37°C 
1:5 C at 37°C 
1:5 C at 37°C 
1:5 C2 deficient serum at 37°C 
" Pro: Properdin . 
b C: Fresh normal human serum at 1:5 d ilu tion. 






FITC labeled ant.isera 
trentment at 37°C 
Anti-Clq, C4, C3, Pro, IgG 
Anti-Clq, C4, C3, Pro, IgG 
Anti-Clq, C<: , C3, Pro, IgG 
Anti-Clq, C4, C3, Pro, IgG 
Anti-Clq, C4, C3, P l:0, IgG 
Anti-CJq, C4, C3, Pro, IgG 









C4 C3 Pro" 
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complex formation of IC antibodies (IgG class) and IC an ti-
gen(s) in the epidermis. 
T he question is how properdin fixation occw"s, i.e., by an 
independent activation of alternative pathway or by an activa-
tion of the C3b amplification mechanism with assembly of the 
C3b dependent C3 convertase following classical activation. 
Wh en C2 deficient serum was used as t he soW"ce of complement 
instead of NHS, complete inhibition of both C3 and properdin 
staining occurred, although binding of Clq and C4 was not 
inhibi ted. B inding of C3 and properdin by IC antibodies th ere-
fore must be the resul ts of the classical pathway activation of 
complement. T hese results suggest that binding of properdin is 
due to generation of the C3b dependent C3 convertase of the 
amplification loop following classical pa thway activation by IC 
antibod ies. 
We are most grateful to those who kindly supplied the sera used in 
the present study and Mrs. Yoshiko F ujii for her excellent technical 
assistance. 
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